Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00984633 | Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED) | PHASE3 | COMPLETED | 40 | — | — | Jun 1, 2003 | Dec 1, 2003 | May 12, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 0.6 mg/kg intubation dose + sevoflurane | EXPERIMENTAL | - |
| 0.9 mg/kg intubation dose + sevoflurane | EXPERIMENTAL | - |
| 0.6 mg/kg intubation dose + propofol | EXPERIMENTAL | - |
| 0.9 mg/kg intubation dose + propofol | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Rocuronium bromide (Org 9426) | DRUG | 0.6 mg/kg injection intubation dose |
| Sevoflurane | DRUG | 0.5-2.0% intravenous maintenance anesthesia |
| Propofol | DRUG | 4-10 mg/kg/hr maintenance anesthesia |
Inclusion Criteria: * Subjects at least 20 but under 65 years of age. * Subjects of asa class 1, 2 or 3 for general elective surgery. * Subjects who are not considered to be pregnant. * Subjects scheduled for elective surgery under sevoflurane or propofol anesthesia, with anticipated duration of su...